Dovitinib

Generic Name: Dovitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁FN_₆O

CAS Number: 405169-16-6

Unique Ingredient Identifier: I35H55G906

Background: Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.

Indication: Investigated for use/treatment in multiple myeloma and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Lung cancer, primarily non-small cell lung cancer (NSCLC), is a leading cause of morbidity and mortality globally. Targeted therapies have emerged as a preferred first-line treatment for NSCLC patients with oncogenic driver mutations, such as EGFR, ALK, ROS1, BRAF, MET, RET, FGFR, and NTRK. These therapies, including small-molecule drugs and monoclonal antibodies, have shown superior efficacy compared to traditional chemotherapy and immunotherapy, particularly in specific molecular subtypes. Challenges remain in drug resistance, adverse effects, and determining optimal treatment sequences. Continued research is essential for advancing precision medicine in lung cancer treatment.

Related Clinical Trials:

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

placera.se

a month ago

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity

A class action lawsuit against Allarity Therapeutics, Inc. and certain officers has been filed, alleging false and misleading statements regarding the Dovitinib NDA's regulatory prospects and improper conduct. The lawsuit seeks damages for violations of federal securities laws and is on behalf of those who acquired Allarity securities between May 17, 2022, and July 19, 2024. Shareholders have until November 12, 2024, to join the lawsuit.